肿瘤化疗药物接触者 5 号和 7 号染色体异常。
Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs.
机构信息
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
出版信息
J Occup Environ Med. 2010 Oct;52(10):1028-34. doi: 10.1097/JOM.0b013e3181f73ae6.
OBJECTIVE
To determine the frequency of "signature" chromosomal abnormalities in oncology workers handling anticancer drugs.
METHODS
Peripheral blood from health care personnel (N = 109) was examined with probes for targets on chromosomes 5, 7, and 11. The effect of drug-handling frequency on chromosome abnormalities was assessed.
RESULTS
An excess of structural (0.18 vs 0.02; P = 0.04) and total abnormalities (0.29 vs 0.04; P = 0.01) of chromosome 5 was observed in the high-exposure group compared with the unexposed. Increased incidence rate ratios (IRRs) for abnormalities of chromosome 5 (IRR = 1.24; P = 0.01) and for either chromosome 5 or 7 (IRR = 1.20; P = 0.01) were obtained at 100 handling events. Effect sizes were augmented 2- to 4-fold when alkylating agent handling alone was considered.
CONCLUSIONS
Biologically important exposure to genotoxic drugs is apparently occurring in oncology work settings despite reported use of safety practices.
目的
确定处理抗癌药物的肿瘤学工作者“特征性”染色体异常的频率。
方法
用针对染色体 5、7 和 11 上靶标的探针检查了 109 名医护人员的外周血。评估了药物处理频率对染色体异常的影响。
结果
与未暴露组相比，高暴露组染色体 5 的结构异常（0.18 对 0.02；P = 0.04）和总异常（0.29 对 0.04；P = 0.01）过多。染色体 5 异常的发生率比（IRR = 1.24；P = 0.01）和染色体 5 或 7 异常的发生率比（IRR = 1.20；P = 0.01）在处理 100 次事件时增加。当仅考虑烷化剂处理时，效应大小增加了 2 到 4 倍。
结论
尽管报告了安全实践的使用，但在肿瘤学工作环境中显然会发生对遗传毒性药物的生物学上重要的暴露。
Zotero 插件